Rapid Developments in Geographic Atrophy

Current and emerging GA treatments offer hope to affected patients and demonstrate ongoing innovation in this field.

By: Sidra Zafar, MD, Sunir Garg, MD, FACS, FASRS

Ophthalmology Management July 1, 2025 Vol 29, Issue July/August 2025 Page(s): 14, 15, 16, 17

Clinical Scorecard: Rapid Developments in Geographic Atrophy

At a Glance

Category	Detail
Condition
Key Mechanisms
Target Population
Care Setting

Key Highlights

Continuous treatment with pegcetacoplan shows increasing efficacy over time.

Guideline-Based Recommendations

Diagnosis

Utilize OCT and fundus autofluorescence imaging to evaluate GA progression.

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Patients with non-foveal geographic atrophy and varying stages of GA.

Clinical Best Practices

Monitor visual function regularly alongside treatment.

References

Source Article

Sidra Zafar, MD

Specialties: Ophthalmology; geographic atrophy and age-related macular degeneration

Bio: Sidra Zafar, MD, is an ophthalmology author whose work addresses geographic atrophy and age-related macular degeneration. In Ophthalmology Management, she has written about current and emerging treatments for geographic atrophy, including complement inhibitors, photobiomodulation, biologic approaches, and gene therapy platforms.

Sunir Garg

Specialties: Ophthalmology; retina and geographic atrophy

Bio: Sunir Garg, MD, FACS, FASRS, is an ophthalmology author focused on retinal disease, including age-related macular degeneration and geographic atrophy. In Ophthalmology Management, he coauthored a 2025 review on rapid developments in geographic atrophy, discussing currently available treatments and emerging drug, biologic, and gene-therapy approaches intended to slow disease progression.